[go: up one dir, main page]

DZ3295A1 - Anticorps humanises sequestrant un peptide amyloide .beta. - Google Patents

Anticorps humanises sequestrant un peptide amyloide .beta.

Info

Publication number
DZ3295A1
DZ3295A1 DZ013295A DZ013295A DZ3295A1 DZ 3295 A1 DZ3295 A1 DZ 3295A1 DZ 013295 A DZ013295 A DZ 013295A DZ 013295 A DZ013295 A DZ 013295A DZ 3295 A1 DZ3295 A1 DZ 3295A1
Authority
DZ
Algeria
Prior art keywords
humanized antibodies
amyloid beta
beta peptide
sequester
peptide
Prior art date
Application number
DZ013295A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ3295(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of DZ3295A1 publication Critical patent/DZ3295A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DZ013295A 2000-02-24 2001-02-26 Anticorps humanises sequestrant un peptide amyloide .beta. DZ3295A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18460100P 2000-02-24 2000-02-24
US25449800P 2000-12-08 2000-12-08
US25446500P 2000-12-08 2000-12-08
PCT/US2001/006191 WO2001062801A2 (fr) 2000-02-24 2001-02-26 Anticorps humanises sequestrant un peptide a$g(b)

Publications (1)

Publication Number Publication Date
DZ3295A1 true DZ3295A1 (fr) 2001-08-30

Family

ID=27391859

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013295A DZ3295A1 (fr) 2000-02-24 2001-02-26 Anticorps humanises sequestrant un peptide amyloide .beta.

Country Status (32)

Country Link
US (4) US7195761B2 (fr)
EP (4) EP1257584B2 (fr)
JP (2) JP4738696B2 (fr)
KR (1) KR100767146B1 (fr)
CN (3) CN101670105B (fr)
AT (1) ATE279442T1 (fr)
AU (1) AU4178601A (fr)
BR (1) BRPI0108676B8 (fr)
CA (1) CA2400559C (fr)
CY (1) CY1118381T1 (fr)
CZ (2) CZ304211B6 (fr)
DE (2) DE60106394T3 (fr)
DK (2) DK1257584T4 (fr)
DZ (1) DZ3295A1 (fr)
EA (1) EA006606B1 (fr)
ES (2) ES2611427T3 (fr)
HK (1) HK1048640B (fr)
HR (2) HRP20020693B1 (fr)
HU (2) HUP0204074A3 (fr)
IL (3) IL151378A0 (fr)
LT (1) LT1481992T (fr)
MX (1) MXPA02008145A (fr)
NO (2) NO329840B1 (fr)
NZ (1) NZ520800A (fr)
PL (2) PL210157B1 (fr)
PT (2) PT1257584E (fr)
SI (2) SI1481992T1 (fr)
SK (2) SK288711B6 (fr)
TR (1) TR200202799T3 (fr)
UA (1) UA75881C2 (fr)
WO (1) WO2001062801A2 (fr)
ZA (1) ZA200206712B (fr)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ES2312348T3 (es) 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
DZ3295A1 (fr) 2000-02-24 2001-08-30 Anticorps humanises sequestrant un peptide amyloide .beta.
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
ATE409047T1 (de) * 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
ATE420114T1 (de) * 2001-04-30 2009-01-15 Lilly Co Eli Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;
AU2002345843A1 (en) * 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
DE60226036T9 (de) † 2001-08-03 2016-09-29 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
EP1519740A4 (fr) * 2001-08-17 2005-11-09 Lilly Co Eli Amelioration rapide des processus cognitifs dans les etats pathologiques lies a l'a-beta
US20040241164A1 (en) * 2001-08-17 2004-12-02 Bales Kelly Renee Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
ATE381346T1 (de) * 2001-08-17 2008-01-15 Univ Washington Assayverfahren für alzheimer-krankheit
JP2005503789A (ja) * 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
AU2002329775C1 (en) 2001-08-17 2011-04-07 Eli Lilly And Company Assay method for alzheimer's disease
US7179606B2 (en) * 2001-11-23 2007-02-20 Syn X Pharma, Inc. IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2003090772A1 (fr) * 2002-04-25 2003-11-06 Eli Lilly And Company Procede pour traiter l'anxiete et les troubles de l'humeur chez des sujets ages
WO2004029629A1 (fr) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. Anticorps monoclonaux beta-amyloide n-11 tronques, compositions, methodes et utilisations
FR2846667B1 (fr) * 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
EP1596809B1 (fr) 2003-02-10 2010-05-26 Applied Molecular Evolution, Inc. Molecules de liaison au peptide abeta
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
KR101435167B1 (ko) 2003-06-27 2014-11-04 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
KR101139103B1 (ko) * 2003-09-12 2012-07-05 아피리스 아게 아페레시스 장치
US7848543B2 (en) * 2004-02-05 2010-12-07 Brainlab Ag Method and system for prediction and management of material and information transport in an organism
UA93181C2 (ru) * 2004-02-23 2011-01-25 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
EP1741783A4 (fr) 2004-04-27 2009-05-27 Chemo Sero Therapeut Res Inst Anticorps de beta peptide antiamyloïde humain et fragment anticorps de celui-ci
CA2572602A1 (fr) * 2004-07-02 2006-02-09 Northwestern University Anticorps monoclonaux ciblant des ensembles pathologiques d'amyloides .beta. (abeta)
US20060024667A1 (en) 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
CN101027391A (zh) * 2004-10-05 2007-08-29 惠氏公司 用于改善重组蛋白质产生的方法和组合物
US9901413B2 (en) * 2004-10-15 2018-02-27 Brainlab Ag Targeted infusion of agents for treatment of ALS
US9924888B2 (en) * 2004-10-15 2018-03-27 Brainlab Ag Targeted infusion of agents against parkinson's disease
US9907485B2 (en) * 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
AR051528A1 (es) * 2004-12-15 2007-01-17 Neuralab Ltd Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20090074775A1 (en) * 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
CA2589860A1 (fr) * 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1896504B1 (fr) 2005-06-17 2012-11-21 Wyeth LLC Procedes de purification des anticorps contenant la region fc
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) * 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
AR057233A1 (es) 2005-12-12 2007-11-21 Hoffmann La Roche Glicosilacion en la region variable
DK2177536T3 (da) * 2006-03-30 2014-07-14 Glaxo Group Ltd Antistoffer mod amyloid-beta-peptid
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (zh) * 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
EP3988566A1 (fr) * 2006-07-14 2022-04-27 AC Immune SA Anticorps humanisés contre le peptide amyloïde-bêta
NO348280B1 (no) * 2006-07-14 2024-11-04 Genentech Inc Humanisert antistoff
ES2436112T3 (es) * 2006-07-14 2013-12-27 Ac Immune S.A. Anticuerpo humanizado
PL2046833T3 (pl) * 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
SI2074145T1 (sl) * 2006-10-02 2017-12-29 Ac Immune S.A. Humanizirano protitelo proti amiloid beta
EP2076287A2 (fr) 2006-10-12 2009-07-08 Wyeth Procédés et compositions ayant une opalescence réduite
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
LT2842967T (lt) 2007-01-18 2017-02-27 Eli Lilly And Company Beta amiloido pegilintas fab
CA2676715A1 (fr) 2007-02-12 2008-08-21 Merck & Co., Inc. Derives de piperazine pour le traitement de la maladie d'alzheimer et des conditions apparentees
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
AU2008254328A1 (en) 2007-05-18 2008-11-27 The Johns Hopkins University A treatment simulator for brain diseases and method of use thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
WO2008156622A1 (fr) * 2007-06-12 2008-12-24 Ac Immune S.A. Anticorps humanisés anti-beta amyloïde
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
US8323647B2 (en) * 2007-09-13 2012-12-04 Delenex Therapeutics Ag Humanized antibodies against the β-amyloid peptide
RU2538709C2 (ru) * 2007-10-05 2015-01-10 Дженентек, Инк. Гуманизированное антитело
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR101377535B1 (ko) 2007-11-16 2014-03-27 더 락커펠러 유니버시티 원섬유 형태의 베타­아밀로이드 단백질에 대해 특이적인 항체
EP2261254A3 (fr) 2007-12-21 2011-04-13 Amgen, Inc Anticorps anti-amyloïdes et leurs utilisations
EP2106802A1 (fr) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Peptides modifiés en tant que vaccins synthétiques dans une maladie associée à l'amyloïde
EP2149380A1 (fr) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Compositions d'immunothérapie vétérinaire pour le disfonctionnement cognitif associé à l'âge
WO2010024927A2 (fr) 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Traitement des amyloïdoses au moyen de protéines basiques de myéline ou de fragments desdites
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
AR079443A1 (es) 2009-12-11 2012-01-25 Araclon Biotech Sl Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides
CA2791648A1 (fr) 2010-03-01 2011-09-09 The J. David Gladstone Institutes Anticorps specifique d'apolipoproteine, et procedes d'utilisation correspondant
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
CA2796339C (fr) 2010-04-15 2020-03-31 Abbott Laboratories Proteines de liaison a la beta amyloide
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
WO2011149461A1 (fr) 2010-05-27 2011-12-01 Medtronic, Inc. Anticorps anti-amyloïde bêta conjugués à des molécules contenant de l'acide sialique
CA2806909C (fr) 2010-07-30 2019-12-17 Ac Immune S.A. Anticorps humanises surs et fonctionnels
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
EP2691393B1 (fr) 2011-03-31 2016-09-14 Pfizer Inc Nouvelles pyridones bicycliques
EP2511296A1 (fr) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Anticorps, kit et procédé pour déterminer des peptides amyloïdes
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
JP2012050437A (ja) * 2011-09-12 2012-03-15 Janssen Alzheimer Immunotherapy ベータアミロイドペプチドを認識するヒト化抗体
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3682905T1 (sl) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
SG10201805622QA (en) 2011-12-22 2018-08-30 Hoffmann La Roche Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2852597B1 (fr) 2012-05-04 2016-06-08 Pfizer Inc Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
AU2013282869B2 (en) 2012-06-29 2015-12-24 Pfizer Inc. Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
EP2869846A4 (fr) * 2012-07-03 2016-01-13 Janssen Alzheimer Immunotherap Anticorps a-bêta contre des épitopes c-terminal et central
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
WO2014091352A1 (fr) 2012-12-11 2014-06-19 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
EP2935282A1 (fr) 2012-12-19 2015-10-28 Pfizer Inc. Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués carbocycliques et hétérocycliques
EP2956458B1 (fr) 2013-02-13 2017-08-09 Pfizer Inc Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
AU2014220351A1 (en) 2013-02-19 2015-08-13 Pfizer Inc. Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of CNS and other disorders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
HRP20240107T1 (hr) 2013-05-20 2024-04-12 F. Hoffmann - La Roche Ag Protutijela na transferinski receptor i postupci uporabe
IL320195A (en) 2013-09-13 2025-06-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
WO2015038884A2 (fr) 2013-09-13 2015-03-19 Genentech, Inc. Compositions et méthodes de détection et de quantification d'une protéine cellulaire hôte dans des lignées cellulaires et polypeptides recombinés
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
WO2015092592A1 (fr) 2013-12-17 2015-06-25 Pfizer Inc. Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
EA031419B1 (ru) 2014-04-01 2018-12-28 Пфайзер Инк. ХРОМЕН И 1,1a,2,7b-ТЕТРАГИДРОЦИКЛОПРОПА[c]ХРОМЕН ПИРИДОПИРАЗИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРА ГАММА-СЕКРЕТАЗЫ
EP3129388A1 (fr) 2014-04-10 2017-02-15 Pfizer Inc. Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle
WO2015165961A1 (fr) 2014-04-29 2015-11-05 Affiris Ag Traitement et prévention de la maladie d'alzheimer
EP3172210B1 (fr) 2014-07-24 2020-01-15 Pfizer Inc Composés de pyrazolopyrimidine
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
WO2016081643A1 (fr) 2014-11-19 2016-05-26 Genentech, Inc. Anticorps anti-récepteur de la transferrine et procédés d'utilisation
SI3221349T1 (sl) 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
WO2016125048A1 (fr) 2015-02-03 2016-08-11 Pfizer Inc. Nouveaux pyridopyrazinediones cyclopropabenzofuranyl
SG10201912333PA (en) 2015-06-17 2020-02-27 Pfizer Tricyclic compounds and their use as phosphodiesterase inhibitors
CN107849125A (zh) 2015-07-21 2018-03-27 生命北极神经科学公司 用于治疗靶向聚集的肽的创伤性脑损伤的方法
CA2992420A1 (fr) 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Procede de reduction de proteines de cellules hotes dans la chromatographie d'affinite
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
EP3353174A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides utiles comme inhibiteurs de bace
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
WO2017051303A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. Dérivés de tétrahydropyrano[3,4-d] [1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AU2016344065A1 (en) 2015-10-28 2018-05-10 The Trustees Of The University Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
WO2017079833A1 (fr) 2015-11-09 2017-05-18 The University Of British Columbia Épitopes dans la région centrale de la bêta-amyloïde et anticorps conformationnels sélectifs associés
WO2017079835A1 (fr) 2015-11-09 2017-05-18 The University Of British Columbia Épitopes de la bêta-amyloïde et anticorps associés
HK1259325A1 (zh) 2015-11-09 2019-11-29 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
US10323042B2 (en) 2016-02-23 2019-06-18 Pfizer Inc. 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
DK3478679T3 (da) 2016-07-01 2021-06-21 Pfizer 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2018014126A1 (fr) 2016-07-18 2018-01-25 The University Of British Columbia Anticorps anti-bêta-amyloïde
CN109562167A (zh) * 2016-08-09 2019-04-02 伊莱利利公司 联合治疗
WO2018064076A1 (fr) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Molécules de récepteurs d'engloutissement chimériques
EP3532034A4 (fr) 2016-10-28 2020-12-02 Washington University Anticorps anti-apoe
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
SG10202110112TA (en) 2017-03-10 2021-10-28 Pfizer Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
EP3592740B1 (fr) 2017-03-10 2022-02-09 Pfizer Inc. Dérivés cycliques substituées de l'imidazo[4,5c]quinoleine.
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EP3634978A1 (fr) 2017-06-07 2020-04-15 Adrx, Inc. Inhibiteur d'agrégation de tau
JP7263266B2 (ja) 2017-06-22 2023-04-24 ファイザー・インク ジヒドロ－ピロロ－ピリジン誘導体
US11530257B2 (en) * 2017-06-29 2022-12-20 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
JP7330164B2 (ja) 2017-07-18 2023-08-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
WO2019023247A1 (fr) 2017-07-25 2019-01-31 Immutics, Inc. Traitement du cancer par blocage de l'interaction de tim-3 et de son ligand
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
AU2018318319A1 (en) 2017-08-18 2020-02-20 Adrx, Inc. Tau aggregation peptide inhibitors
DK3688032T3 (da) 2017-09-26 2025-12-15 Cero Therapeutics Holdings Inc Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase
WO2019074840A1 (fr) * 2017-10-09 2019-04-18 Keith Black Compositions et procédés de traitement de la maladie d'alzheimer et d'autres maladies liées à l'amyloïde
ES2942837T3 (es) 2018-03-23 2023-06-07 Pfizer Derivados de azaespiro piperazina
US20210015865A1 (en) 2018-03-28 2021-01-21 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
KR20210024443A (ko) 2018-03-28 2021-03-05 세로 테라퓨틱스, 인코포레이티드 세포 면역요법 조성물 및 이의 용도
WO2019226690A1 (fr) * 2018-05-21 2019-11-28 New York University Traitement de métastases cérébrales de mélanome par inhibition du clivage de la protéine précurseur de l'amyloïde
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
AU2019354965B2 (en) 2018-10-04 2025-03-27 University Of Rochester Improvement of glymphatic delivery by manipulating plasma osmolarity
TW202035442A (zh) 2018-12-20 2020-10-01 美商建南德克公司 經修飾之抗體Fc及其使用方法
FR3091999A1 (fr) * 2019-01-25 2020-07-31 Mexbrain Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
EP4157338A4 (fr) 2020-05-26 2024-11-13 TrueBinding, Inc. Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
EP4297868A4 (fr) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations
MX2024009597A (es) 2022-02-03 2024-08-15 Lilly Co Eli Imagenologia de tau regional para diagnosticar y tratar la enfermedad de alzheimer.
WO2025032070A1 (fr) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anticorps anti-protéine a-bêta, procédés et utilisations associés
WO2025145091A1 (fr) 2023-12-29 2025-07-03 Pfizer Inc. Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
FR2608669A1 (fr) 1986-12-19 1988-06-24 Boussois Sa Vitrage pret a sa pose et son procede de fabrication et de fixation
US4933156A (en) * 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
PT667959E (pt) * 1992-10-26 2003-12-31 Lilly Co Eli Metodos para identificar inibidores da producao do peptido beta-amiloide
CA2115900A1 (fr) 1993-02-22 1994-08-23 Gerald W. Becker Cribles pharmaceutiques et anticorps
CA2171553A1 (fr) * 1993-09-28 1995-04-06 Charles A. Marotta Utilisation d'oligonucleotiques non codants pour moduler la croissance nerveuse et pour reparer la morphologie induite par l'amyloide .beta./a4
AU692237B2 (en) * 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
EP0996736A1 (fr) * 1997-08-11 2000-05-03 Chiron Corporation Methodes de modification genetique de lymphocytes t
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2325600A1 (fr) 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Procede d'elimination d'amyloide a l'aide d'anticorps anti-amyloide
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ES2312348T3 (es) * 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
AU6524500A (en) 1999-08-04 2001-03-05 Northwestern University Amyloid beta protein (globular assembly and uses thereof)
ATE461996T1 (de) 1999-09-03 2010-04-15 Univ Ramot Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
DZ3295A1 (fr) * 2000-02-24 2001-08-30 Anticorps humanises sequestrant un peptide amyloide .beta.
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
AU2001290638C1 (en) 2000-09-06 2009-04-30 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ATE381346T1 (de) 2001-08-17 2008-01-15 Univ Washington Assayverfahren für alzheimer-krankheit

Also Published As

Publication number Publication date
DK1257584T4 (da) 2013-03-25
KR20020089359A (ko) 2002-11-29
TR200202799T3 (tr) 2003-03-21
EP3150633A1 (fr) 2017-04-05
CN1426423A (zh) 2003-06-25
CA2400559A1 (fr) 2001-08-30
PL210157B1 (pl) 2011-12-30
HK1048640A1 (en) 2003-04-11
BRPI0108676B8 (pt) 2021-05-25
NZ520800A (en) 2004-04-30
PL356798A1 (en) 2004-07-12
ES2184660T3 (es) 2005-05-01
EP1257584A2 (fr) 2002-11-20
NO20083805L (no) 2002-10-22
WO2001062801A3 (fr) 2002-01-31
IL151378A (en) 2010-04-29
HRP20080430A9 (en) 2009-02-28
PT1481992T (pt) 2017-01-02
CZ20022851A3 (cs) 2003-09-17
EA006606B1 (ru) 2006-02-24
HRP20080430A2 (en) 2008-11-30
DK1481992T3 (en) 2017-01-30
SK12212002A3 (sk) 2003-10-07
ATE279442T1 (de) 2004-10-15
WO2001062801A2 (fr) 2001-08-30
NO20023957L (no) 2002-10-22
HRP20020693B1 (hr) 2012-01-31
AU4178601A (en) 2001-09-03
CZ304211B6 (cs) 2014-01-08
IL193631A0 (en) 2009-02-11
ES2184660T5 (es) 2013-05-09
US7195761B2 (en) 2007-03-27
SI1481992T1 (sl) 2017-01-31
IL151378A0 (en) 2003-04-10
BR0108676A (pt) 2003-01-07
US7892545B2 (en) 2011-02-22
CZ2008595A3 (cs) 2017-05-03
CN101670105B (zh) 2014-08-06
EP1257584B1 (fr) 2004-10-13
KR100767146B1 (ko) 2007-10-15
LT1481992T (lt) 2017-02-10
EP1481992B1 (fr) 2016-11-02
JP4738696B2 (ja) 2011-08-03
CA2400559C (fr) 2012-05-01
DE60106394D1 (de) 2004-11-18
SK288711B6 (sk) 2019-11-05
CN104341500A (zh) 2015-02-11
DE60106394T3 (de) 2013-07-25
HUP0204074A2 (hu) 2003-03-28
EP3070100A1 (fr) 2016-09-21
ES2611427T3 (es) 2017-05-08
DE60106394T2 (de) 2006-03-09
ZA200206712B (en) 2003-11-21
HRP20020693A2 (en) 2004-12-31
CY1118381T1 (el) 2017-06-28
EP1481992A3 (fr) 2004-12-08
HUP0800571A2 (en) 2003-03-28
US20090238821A1 (en) 2009-09-24
NO329840B1 (no) 2011-01-10
EP1257584B9 (fr) 2004-12-01
JP2009046497A (ja) 2009-03-05
EA200200897A1 (ru) 2003-02-27
HRP20080430B1 (hr) 2016-12-16
CN1426423B (zh) 2010-05-12
PT1257584E (pt) 2005-01-31
US20110158986A1 (en) 2011-06-30
EP1481992A2 (fr) 2004-12-01
NO20023957D0 (no) 2002-08-20
SI1257584T1 (en) 2005-04-30
EP1257584B2 (fr) 2013-03-06
IL193631A (en) 2010-11-30
CN101670105A (zh) 2010-03-17
ES2184660T1 (es) 2003-04-16
SK288723B6 (sk) 2020-01-07
CZ306683B6 (cs) 2017-05-03
HU230768B1 (hu) 2018-03-28
US20040043418A1 (en) 2004-03-04
US20060039906A1 (en) 2006-02-23
SI1257584T2 (sl) 2013-07-31
JP2003523764A (ja) 2003-08-12
UA75881C2 (en) 2006-06-15
MXPA02008145A (es) 2004-04-05
BRPI0108676B1 (pt) 2015-09-15
DK1257584T3 (da) 2005-01-17
HK1048640B (en) 2005-04-01
PL218883B1 (pl) 2015-02-27
DE1257584T1 (de) 2003-05-28
JP4914412B2 (ja) 2012-04-11
US8591894B2 (en) 2013-11-26
EP3070100B1 (fr) 2021-07-07
HUP0204074A3 (en) 2004-07-28
NO337363B1 (no) 2016-03-29

Similar Documents

Publication Publication Date Title
DZ3295A1 (fr) Anticorps humanises sequestrant un peptide amyloide .beta.
WO2002046237A3 (fr) Anticorps humanises reconnaissant le peptide amyloide beta
IL165193A (en) Humanized immunomodulatory monoclonal antibodies and use thereof for the treatment of neoplastic disease
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
WO2003016467A3 (fr) Utilisation d'anticorps ayant une forte affinite pour le peptide a$g(b) dans le traitement de pathologies et de maladies liees a a$g(b)
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
ZA200609407B (en) Monoclonal antibodies to hepatocyte growth factor
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
UA41984C2 (uk) Спосіб інгібування утворення тромбів у людини (варіанти), спосіб лікування людини для зниження у людини небезпеки постхірургічних тромботичних ускладнень (варіанти),спосіб лікування тромботичного судинного захворювання у людини (варіанти), фармацевтична композиція, що містить некон'юговане антифібринове моноклональне антитіло мн-1, фармацевтична композиція, що містить некон'югований фрагмент або похідне антифібринового моноклонального антитіла мн-1, набір для лікування людини, що потребує інгібування утворення тромбу
EP1645285A3 (fr) Utilisation thérapeutique d'anticorps anti-mag pour traiter l'accident ischèmique
AU2001280256A1 (en) Methods for the diagnosis and/or treatment of diseases related to anti-phospholipid antibodies and devices used therein